Title of article :
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Author/Authors :
Kim A. Papp، نويسنده , , Richard G Langley، نويسنده , , Mark Lebwohl، نويسنده , , Gerald G Krueger، نويسنده , , Philippe Szapary، نويسنده , , Newman Yeilding، نويسنده , , Cynthia Guzzo، نويسنده , , Ming-Chun Hsu، نويسنده , , Yuhua Wang، نويسنده , , Shu Li، نويسنده , , Lisa T Dooley، نويسنده , , Kristian Reich، نويسنده ,
Abstract :
Background
Ustekinumab, a human monoclonal antibody against interleukins 12 and 23, has shown therapeutic potential for psoriasis. This study assessed the efficacy and safety of ustekinumab in psoriasis patients and assessed dosing intensification in part
